WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer

Cancer Immunology, Immunotherapy

Volumn 59, Issue 10, 2010, Pages 1467-1479

  Krug, Lee M ^a   Dao, Tao ^a   Brown, Andrew B ^a   Maslak, Peter ^a   Travis, William ^a   Bekele, Sara ^a   Korontsvit, Tatyana ^a   Zakhaleva, Victoria ^a   Wolchok, Jedd ^a   Yuan, Jianda ^a   Li, Hao ^a   Tyson, Leslie ^a   Scheinberg, David A ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Mesothelioma; Non small cell lung cancer; Vaccine; WT1

Indexed keywords

CANCER VACCINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA A ANTIGEN; MONTANIDE ISA 51; PEPTIDE VACCINE; UNCLASSIFIED DRUG; WT1 PEPTIDE VACCINE;

ADJUVANT THERAPY; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNIZATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFICACY; DRUG SAFETY; DRUG SPECIFICITY; DRUG STRUCTURE; FEMALE; HEMATOLOGIC DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE PRURITUS; INJECTION SITE REACTION; INJECTION SITE SWELLING; KIDNEY DISEASE; LUNG DISEASE; LUNG NON SMALL CELL CANCER; LYMPHOCYTE PROLIFERATION; MALE; MESOTHELIOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TREATMENT DURATION;

AGED; AGED, 80 AND OVER; AMINO ACID SEQUENCE; CANCER VACCINES; CARCINOMA, NON-SMALL-CELL LUNG; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; MALE; MESOTHELIOMA; MIDDLE AGED; MOLECULAR SEQUENCE DATA; NEOPLASM STAGING; PEPTIDE FRAGMENTS; WT1 PROTEINS;

EID: 77955553483     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-010-0871-8     Document Type: Article

References (27)

1. U Keilholz HD Menssen A Gaiger A Menke Y Oji Y Oka C Scheibenbogen H Stauss E Thiel H Sugiyama 2005 Wilms' tumour gene 1 (WT1) in human neoplasia Leukemia 19 1318 1323 10.1038/sj.leu.2403817 1:CAS:528:DC%2BD2MXmtlSjsrk%3D 15920488 (Pubitemid 41136321)
2. Y Oji H Ogawa H Tamaki Y Oka A Tsuboi EH Kim T Soma T Tatekawa M Kawakami M Asada T Kishimoto H Sugiyama 1999 Expression of the Wilms' tumor gene WT1 in solid tumors and its involvement in tumor cell growth Jpn J Cancer Res 90 194 204 1:CAS:528:DyaK1MXisVylur8%3D 10189890
3. K Inoue H Ogawa Y Sonoda T Kimura H Sakabe Y Oka S Miyake H Tamaki Y Oji T Yamagami T Tatekawa T Soma T Kishimoto H Sugiyama 1997 Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia Blood 89 1405 1412 1:CAS:528:DyaK2sXhtFantLs%3D 9028964
4. C Rosenfeld MA Cheever A Gaiger 2003 WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapies Leukemia 17 1301 1312 10.1038/sj.leu.2402988 1:CAS:528:DC%2BD3sXkvFeqsLk%3D 12835718 (Pubitemid 36857337)
5. KM Amin LA Litzky WR Smythe AM Mooney JM Morris DJ Mews HI Pass C Kari U Rodeck FJ Rauscher 3rd, et al. 1995 Wilms' tumor 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma Am J Pathol 146 344 356 1:STN:280:DyaK2M7mtVWgsQ%3D%3D 7856747
6. V Scharnhorst P Dekker AJ van der Eb AG Jochemsen 1999 Internal translation initiation generates novel WT1 protein isoforms with distinct biological properties J Biol Chem 274 23456 23462 10.1074/jbc.274.33.23456 1:CAS:528:DyaK1MXltlKnu7w%3D 10438524 (Pubitemid 29388101)
7. DA Haber RL Sohn AJ Buckler J Pelletier KM Call DE Housman 1991 Alternative splicing and genomic structure of the Wilms tumor gene WT1 Proc Natl Acad Sci USA 88 9618 9622 10.1073/pnas.88.21.9618 1:CAS:528: DyaK3sXhslagug%3D%3D 1658787 (Pubitemid 21915682)
8. J Oates C Edwards 2000 HBME-1, MOC-31, WT1 and calretinin: an assessment of recently described markers for mesothelioma and adenocarcinoma Histopathology 36 341 347 10.1046/j.1365-2559.2000.00770.x 1:STN:280:DC%2BD3c3itlCgtA%3D%3D 10759948 (Pubitemid 30198916)
9. MR Foster JE Johnson SJ Olson DC Allred 2001 Immunohistochemical analysis of nuclear versus cytoplasmic staining of WT1 in malignant mesotheliomas and primary pulmonary adenocarcinomas Arch Pathol Lab Med 125 1316 1320 1:CAS:528:DC%2BD3MXotVejsb0%3D 11570906
10. NG Ordonez 2003 The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma Am J Surg Pathol 27 1031 1051 10.1097/00000478-200308000-00001 12883236 (Pubitemid 36909525)
11. MA Cheever JP Allison AS Ferris OJ Finn BM Hastings TT Hecht I Mellman SA Prindiville JL Viner LM Weiner LM Matrisian 2009 The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research Clin Cancer Res 15 5323 5337 10.1158/1078-0432.CCR-09- 0737 19723653
12. Y Oka A Tsuboi T Taguchi T Osaki T Kyo H Nakajima OA Elisseeva Y Oji M Kawakami K Ikegame N Hosen S Yoshihara F Wu F Fujiki M Murakami T Masuda S Nishida T Shirakata S Nakatsuka A Sasaki K Udaka H Dohy K Aozasa S Noguchi I Kawase H Sugiyama 2004 Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression Proc Natl Acad Sci USA 101 13885 13890 10.1073/pnas.0405884101 1:CAS:528: DC%2BD2cXotVygtbY%3D 15365188 (Pubitemid 39298502)
13. U Keilholz A Letsch A Busse AM Asemissen S Bauer IW Blau WK Hofmann L Uharek E Thiel C Scheibenbogen 2009 A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS Blood 113 6541 6548 10.1182/blood-2009-02-202598 1:CAS:528: DC%2BD1MXotlWrurk%3D 19389880
14. J Pinilla-Ibarz RJ May T Korontsvit M Gomez B Kappel V Zakhaleva RH Zhang DA Scheinberg 2006 Improved human T-cell responses against synthetic HLA-0201 analog peptides derived from the WT1 oncoprotein Leukemia 20 2025 2033 10.1038/sj.leu.2404380 1:CAS:528:DC%2BD28XhtFWnsLzI 16990779 (Pubitemid 44614893)
15. RJ May T Dao J Pinilla-Ibarz T Korontsvit V Zakhaleva RH Zhang P Maslak DA Scheinberg 2007 Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells Clin Cancer Res 13 4547 4555 10.1158/1078-0432.CCR-07- 0708 1:CAS:528:DC%2BD2sXotlGqu78%3D 17671141 (Pubitemid 47219725)
16. TJ Yao CB Begg PO Livingston 1996 Optimal sample size for a series of pilot trials of new agents Biometrics 52 992 1001 10.2307/2533060 1:STN:280:DyaK28zpvFWqsQ%3D%3D 8805764
17. MJ Byrne AK Nowak 2004 Modified RECIST criteria for assessment of response in malignant pleural mesothelioma Ann Oncol 15 257 260 10.1093/annonc/mdh059 1:STN:280:DC%2BD2c%2FlvVamtg%3D%3D 14760119 (Pubitemid 38262625)
18. MS von Bergwelt-Baildon RH Vonderheide B Maecker, et al. 2002 Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application Blood 99 3319 3325 10.1182/blood.V99.9.3319 1:CAS:528:DC%2BD38XjtlGqsLo%3D 11964299 (Pubitemid 34525313)
19. RA Seder PA Darrah M Roederer 2008 T-cell quality in memory and protection: implications for vaccine design Nat Rev Immunol 8 247 258 10.1038/nri2274 1:CAS:528:DC%2BD1cXjs1antLk%3D 18323851 (Pubitemid 351432801)
20. MA Perales J Yuan S Powel HF Gallardo TS Rasalan C Gonzalez G Manukian J Wang Y Zhang PB Chapman SE Krown PO Livingston S Ejadi KS Panageas ME Engelhorn SL Terzulli AN Houghton JD Wolchok 2008 Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma Mol Ther 16 2022 2029 10.1038/mt.2008.196 1:CAS:528:DC%2BD1cXhsVSjsbnK 18797450
21. Letsch A, Elisseeva OA, Scheibenbogen C, Asemissen A, Stather D, Busse A, Oka Y, Keilholz U, Sugiyama H, Thiel E (2008) Effect of vaccination of leukemia patients with a MHC class I peptide of Wilms tumor gene 1 (WT1) peptide with unspecific T helper stimulation on WT1-specific IgM responses and on IgG responses. J Clin Oncol 26:Abstr 3054
22. K Rezvani AS Yong S Mielke BN Savani L Musse J Superata B Jafarpour C Boss AJ Barrett 2008 Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies Blood 111 236 242 10.1182/blood-2007-08-108241 1:CAS:528: DC%2BD1cXjtVKiug%3D%3D 17875804
23. JK Sandberg NM Fast DF Nixon 2001 Functional heterogeneity of cytokines and cytolytic effector molecules in human CD8+ T lymphocytes J Immunol 167 181 187 1:CAS:528:DC%2BD3MXkslSqtbk%3D 11418647
24. M Lichterfeld XG Yu MT Waring SK Mui MN Johnston D Cohen MM Addo J Zaunders G Alter E Pae D Strick TM Allen ES Rosenberg BD Walker M Altfeld 2004 HIV-1-specific cytotoxicity is preferentially mediated by a subset of CD8(+) T cells producing both interferon-gamma and tumor necrosis factor-alpha Blood 104 487 494 10.1182/blood-2003-12-4341 1:CAS:528:DC%2BD2cXlvFSnurk%3D 15059848 (Pubitemid 38900032)
25. LM Krug HI Pass VW Rusch HL Kindler DJ Sugarbaker KE Rosenzweig R Flores JS Friedberg K Pisters M Monberg CK Obasaju NJ Vogelzang 2009 Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma J Clin Oncol 27 3007 3013 10.1200/JCO.2008.20.3943 1:CAS:528:DC%2BD1MXoslyisLo%3D 19364962
26. NJ Vogelzang JJ Rusthoven J Symanowski C Denham E Kaukel P Ruffie U Gatzemeier M Boyer S Emri C Manegold C Niyikiza P Paoletti 2003 Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma J Clin Oncol 21 2636 2644 10.1200/JCO.2003.11.136 1:CAS:528:DC%2BD2cXptlCktL4%3D 12860938 (Pubitemid 46606305)
27. A Hoos G Parmiani K Hege M Sznol H Loibner A Eggermont W Urba B Blumenstein N Sacks U Keilholz G Nichol 2007 A clinical development paradigm for cancer vaccines and related biologics J Immunother 30 1 15 10.1097/01.cji. 0000211341.88835.ae 17198079 (Pubitemid 46052199)